- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01246921
Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo
Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial
Rationale: Vitiligo vulgaris is a common acquired pigment disorder, which is characterised by the development of depigmented macules. It develops probably due to immunedestruction of melanocytes. Most effective therapies are immunsuppresive:
- local immunesuppressives like corticosteroids and calcineurin inhibitors
- phototherapy like PUVA and NB-UVB phototherapy. NB-UVB is the first choice A synergistic effect of UVA and topical corticosteroids (fluticasone proprionate 0.05% cream) has been described by Westerhof et al. in 1999. To our knowledge to date there are no publications comparing NB-UVB combined with a topical corticosteroid and NB-UVB alone.
Objective: The objective of this study is to evaluate the clinical effects (onset and degree of repigmentation) of fluticasone proprionate 0.05% cream (thrice weekly) on NB-UVB phototherapy twice weekly for a period of 12 months.
Study design: Prospective single blinded randomised controlled study. Study population: Consecutive patients ≥ 18 years, diagnosed with active vitiligo vulgaris who will receive NB-UVB phototherapeutic treatment at the Netherlands Institute for Pigment Disorders at the Academic Medical Centre (AMC), University of Amsterdam.
Methods: The patient will be randomised for either NB-UVB phototherapy and fluticasone proprionate 0.05% cream or NB-UVB phototherapy alone for 12 consecutive months.
Main study parameters/endpoints: The onset and degree of repigmentation is assessed by digital image analysis of a target lesion and blinded global physician assessment. Furthermore, the patients and doctors satisfaction will be assessed and changes of immunohistochemical parameters will be analysed in skin biopsies.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects participating in the study will be asked to visit the institute 4 times. The time investment will be 20 minutes per visit. Additionally, patients will be asked for consent to take punch biopsies (3 mm) at the beginning and at the end of the treatment period. Hence, skin biopsies are not compulsory for participation in this study. Patients may chose to participate in the clinical non invasive part of the study. Known side effects of the NB-UVB phototherapy are redness, pruritus, xerosis cutis, burning sensation and conjunctivitis. These side-effects however, are largely dose-dependent and avoidable. Corticosteroid associated systemic side-effects (suppression of the adrenocortex) will be minimized by treating only a limited body surface [a maximum of 30% body surface] and by using an intermittent application scheme of three days a week in the long term treatment. The regions which are known to have a higher absorption are excluded (periorbital, axillary, inguinal and genital area). Both topical corticosteroids and NB-UVB are part of the Dutch and British guidelines for the treatment of vitiligo. There is no presumptive evidence or indication that the combination of these therapies may result in a higher risk of side effects.
All together the burden due to the study is low and the risk for systemic or local side effects is low.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Marije Kroon, M.D.
- Phone Number: +31205666955
- Email: mwkroon@gmail.com
Study Locations
-
-
-
Amsterdam, Netherlands, 1105AZ
- Recruiting
- Netherlands Institute for Pigments Disorders
-
Principal Investigator:
- Albert Wolkerstorfer, M.D. PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- non-segmental vitiligo
- Eligible for NB-UVB therapy
- Subjects attending the outpatient department of the SNIP
- patients > 18 years
- Skin type II-V
- patients with active vitiligo: progression of older lesions or development of new lesion during the last 6 months
- Subject is willing and able to give written informed consent
Exclusion Criteria:
- Personal or a family history of skin cancer ( non-melanoma skincancer: first degree family members, melanoma: any family members)
- Personal history of photosensitivity and/or phototoxicity disorders
- pregnancy
- Taking medication known to cause photosensitivity, phototoxicity, immune suppression and chronic or very frequent use of any medication that can influence the UVB response (e.g. tetracycline, retinoids, sulfonamids, psoralens)
- Other skin diseases that would impair the evaluation of repigmentation
- not able to have 2 times weekly NB-UVB phototherapy
- With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weeks will be required.
- Contact-allergy for any of the parts in fluticasone proprionate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: fluticasone proprionate 0.05 %
Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
|
Fluticasone proprionate 0.05% cream .
In each patient a representative target lesion will be selected which will be assessed by digital analysis.
Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months.
I nthe following 9 months FP will be applied in a scheme of 3 days per week
Other Names:
|
No Intervention: no intervention
Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Repigmentation of the vitiligo lesions
Time Frame: 15 months
|
Degree of repigmentation is assessed by digital analysis of a target lesion by a blinded global physician assessment
|
15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients satisfaction
Time Frame: 15 months
|
satisfaction/preference
|
15 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNIP_UVB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Active Non-segmental Vitiligo.
-
Cairo UniversityCompletedActive Non Segmental VitiligoEgypt
-
PfizerCompletedActive Non-segmental VitiligoSpain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
-
Merck Sharp & Dohme LLCRecruitingNon-segmental VitiligoUnited States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium
-
Incyte CorporationCompletedNon-segmental VitiligoUnited States, Canada, Italy, France, Germany, Spain, Poland, Bulgaria, Netherlands
-
Sohag UniversityNot yet recruiting
-
Nicolaus Copernicus UniversityCompleted
-
Sun Pharmaceutical Industries LimitedCompletedNon-segmental VitiligoUnited States, India
-
Nicolaus Copernicus UniversityCompleted
-
Netherlands Institute for Pigment DisordersAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Avita MedicalTerminated
-
AbbVieCompletedNon-Segmental VitiligoUnited States, Canada, France, Japan
Clinical Trials on Fluticasone proprionate 0.05% cream
-
Therapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Padagis LLCCompleted
-
Arcutis Biotherapeutics, Inc.CompletedAtopic DermatitisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis (Eczema)United States
-
Arcutis Biotherapeutics, Inc.Active, not recruitingAtopic Dermatitis EczemaUnited States, Canada
-
G & W Laboratories Inc.CompletedPlaque PsoriasisUnited States
-
NeoStrata Company, Inc.Massachusetts General HospitalUnknownEczema | Dermatitis, AtopicUnited States
-
Procter & Gamble BeautyCompletedEczema | Dermatitis, AtopicUnited States
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedArsenical KeratosisBangladesh
-
Kari NadeauKing's College London; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, InfantileUnited States, United Kingdom